« Back
Home /
Ondansetron (hydrochloride dihydrate)

Ondansetron (hydrochloride dihydrate)

Item no.	HY-B0002A-1g
Manufacturer	MedChem Express
CASRN	103639-04-9
Amount	1 g
Quantity options	100 mg 10 mMx1 mL 1 g 50 mg 5 g
Category	Metabolism Regulation of Appetite Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.94
Citations	[1]Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65.\|[2]Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):255-65. \|[3]Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50. \|[4]Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16.\|[5]Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83.\|[6]Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31. \|[7]Xin Wang, et al. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. Cell Biochem Biophys. 2015 Jun;72(2):471-3. \|[8]Azadeh Motavallian-Naeini, et al. Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat. EXCLI J2012 Feb 22:11:30-44. eCollection 2012. \|[9]허원석. Effects of ondansetron on the activity of glutamate transporter type 3 and the modulation mechanism[D]. 서울대학교 대학원, 2014. Eur J Pharm Sci. 2023 Aug 1:187:106475. Int J Pharm. 2015 Dec 30;496(1):33-41. Patent. US20170319486A1. Adv Sci (Weinh). 2025 Apr 7:e2503739. Biochem Biophys Res Commun. 2025 Oct 30:786:152756. Front Pharmacol. 2024 Aug 21:15:1443169. J Ethnopharmacol. 2024 Apr 6:323:117703. J Radiat Res Appl Sci. 2023 Dec, 16(4), 100682. Prog Neuropsychopharmacol Biol Psychiatry. 2023 Mar 2:122:110689. SSRN. 2023 Srep 5.
Smiles	O=C1C(CN2C=CN=C2C)CCC(N3C)=C1C4=C3C=CC=C4.[H]Cl.O.O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GR 38032 (hydrochloride dihydrate),SN 307 (hydrochloride dihydrate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	5-HT Receptor
Manufacturer - HS Code	H301
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	365.85
Product Description	Ondansetron (GR 38032; SN 307) hydrochloride dehydrate is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron hydrochloride dehydrate exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron hydrochloride dehydrate can inhibit nausea and vomiting induced by chemotherapy and radiotherapy[1][2][3][4][5][6][7][8].
Manufacturer - Research Area	Neurological Disease
Solubility	DMSO : 100 mg/mL (ultrasonic)\|H2O : 16.67 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Clinical information	Launched
Isoform	lactoferrin
UNSPSC Code	12352005
Precautionary	H301

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.